Dalil Davood, Iranzadeh Saeid, Kohansal Soroush
Student Research Committee, Faculty of Medicine, Shahed University, Tehran, Iran.
Front Pharmacol. 2022 Sep 16;13:979634. doi: 10.3389/fphar.2022.979634. eCollection 2022.
Breast cancer has recently been known as the first lethal malignancy in women worldwide. Despite the existing treatments that have improved the patients' prognosis, some types of breast cancer are serious challenges to treat. Therefore, efforts are underway to provide more efficient therapy. Cryptotanshinone (CPT) is a liposoluble diterpenoid derivation of a traditional Chinese herbal medicine called Salvia miltiorrhiza Bunge. It has been considered in the past decades due to its vast therapeutic properties, including anti-tumor, anti-inflammatory, and anti-fibrosis. Recently, studies have found that CPT showed a significant anti-breast cancer effect and through different physiological and immunological mechanisms. This study summarized the latest research findings on the antitumor effect of CPT in breast cancer. Further, the main molecular mechanisms based on breast cancer types and combination with other drugs were reviewed to provide essential evidence for future longitudinal research and its clinical application in breast cancer treatment.
乳腺癌最近已成为全球女性中首要的致死性恶性肿瘤。尽管现有治疗方法改善了患者的预后，但某些类型的乳腺癌治疗仍面临严峻挑战。因此，人们正在努力提供更有效的治疗方法。隐丹参酮（CPT）是一种从传统中药丹参中提取的脂溶性二萜类衍生物。在过去几十年中，因其具有广泛的治疗特性，包括抗肿瘤、抗炎和抗纤维化作用，而受到关注。最近，研究发现CPT通过不同的生理和免疫机制显示出显著的抗乳腺癌作用。本研究总结了CPT在乳腺癌中抗肿瘤作用的最新研究结果。此外，还综述了基于乳腺癌类型以及与其他药物联合使用的主要分子机制，为未来的纵向研究及其在乳腺癌治疗中的临床应用提供重要依据。
